

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM824825

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest in Specified Trademarks at Reel/Frame 6280/0114		
SEQUENCE:	2		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Barclays Bank PLC		07/14/2023	Public Limited Company: UNITED KINGDOM
RECEIVING PARTY DATA			
Name:	Bausch Health Companies Inc. (f/k/a Valeant Pharmaceuticals International, Inc.)		
Street Address:	2150 ST. ELZÉAR BLVD. WEST, LAVAL		
City:	QUEBEC		
State/Country:	CANADA		
Postal Code:	H7L 4A8		
Entity Type:	Corporation: CANADA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	2893833	ERTACZO	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	8004945225		
Email:	ipteam@coagencyglobal.com		
Correspondent Name:	JAY DASILVA		
Address Line 1:	1025 CONNECTICUT AVE., NW, STE. 712		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	WASHINGTON, D.C. 20036		
ATTORNEY DOCKET NUMBER:	2067071 TM REL 2		
NAME OF SUBMITTER:	Dahlia Gottlieb		
SIGNATURE:	/Dahlia Gottlieb/		
DATE SIGNED:	07/17/2023		
Total Attachments: 5			

OP \$40.00 2893833

source=Ertaczo - Trademark Release (Barclays) [executed]#page1.tif
source=Ertaczo - Trademark Release (Barclays) [executed]#page2.tif
source=Ertaczo - Trademark Release (Barclays) [executed]#page3.tif
source=Ertaczo - Trademark Release (Barclays) [executed]#page4.tif
source=Ertaczo - Trademark Release (Barclays) [executed]#page5.tif

**RELEASE OF
SECURITY INTEREST IN SPECIFIED TRADEMARKS**

This RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS (this “Release”) is entered into as of July 14, 2023 by Barclays Bank PLC, a public limited company, as collateral agent for the Secured Parties (in such capacity and together with its successors and assigns, the “Collateral Agent”) (the “Assignor”), in favor of Bausch Health Companies Inc. (f/k/ a Valeant Pharmaceuticals International, Inc.), a corporation continued under the laws of the Province of British Columbia (the “Assignee”). Reference is made to the Fourth Amended and Restated Credit and Guaranty Agreement, dated as of June 1, 2018 (as amended by the First Incremental Amendment dated as of November 27, 2018, by the Second Amendment dated as of May 10, 2022, and as further amended, restated, replaced, supplemented or otherwise modified from time to time, the “Credit Agreement”) and U.S. Pledge and Security Agreement (as amended, restated, amended and restated and as otherwise supplemented from time to time, the “Pledge and Security Agreement”). Capitalized terms used in this Release but not defined herein shall have the respective meanings ascribed to such terms in the Credit Agreement, Pledge and Security Agreement, and the Trademark Security Agreements (as defined below), as applicable.

WHEREAS, reference is made to (i) that certain Notice of Succession of Agency and Transfer of Security Interest, dated as of January 8, 2015 between Goldman Sachs Lending Partners LLC (as Prior Agent) and the Assignor (as Successor Agent) (the “January 2015 Trademark Security Agreement”), (ii) that certain Trademark Security Agreement, dated as of February 13, 2018 between the Assignor (as Collateral Agent), the Assignee and other grantors party thereto (the “February 2018 Trademark Security Agreement”), and (iii) that certain Amended and Restated Pledge and Security Agreement, dated June 1, 2018, among the Collateral Agent and the Assignee and other grantors party thereto (the “June 2018 Amended and Restated Pledge and Security Agreement”, together with the January 2015 Trademark Security Agreement and the February 2018 Trademark Security Agreement, the “Trademark Security Agreements”, and each a “Trademark Security Agreement”).

WHEREAS, pursuant to the terms and conditions of each Trademark Security Agreement, the Assignee granted to the Assignor, for the benefit of the Secured Parties, a security interest in and continuing lien on all of the Assignee’s right, title and interest in, to and under the following, in each case whether then owned or thereafter acquired by the Assignee or in which the Assignee then had or thereafter acquired any right, title or interest and wherever the same may be located (collectively, the “Trademark Collateral”):

all United States and foreign trademarks, trade names, trade dress, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, whether or not registered, and with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications listed in Schedule A attached to each Trademark Security Agreement, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past,

present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world;

WHEREAS, the January 2015 Trademark Security Agreement was recorded with the United States Patent and Trademark Office on January 9, 2015 at Reel 5439, Frame 0392;

WHEREAS, the February 2018 Trademark Security Agreement was recorded with the United States Patent and Trademark Office on February 26, 2018 at Reel 6280, Frame 0114.

WHEREAS, in reliance on Bausch Health Companies Inc.'s representations concerning the transactions referenced in that certain Officer's Certificate, dated July 14, 2023 (the "Certificate"), the Assignor has agreed to terminate and release its security interest solely in the Specified Trademarks (as defined in Schedule I hereto) and Specified Trademark Collateral (as defined below) related thereto.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor, on behalf of itself, its successors, legal representatives and assigns and any lenders for which the Assignor acted as security or collateral agent, hereby unconditionally terminates, releases, discharges and reassigns to the Assignee fully, without representation, warranty or recourse, its security interest in and continuing lien on all of the Assignee's right, title and interest in, to and under (i) the Specified Trademarks, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto (but excluding, for the avoidance of doubt, Proceeds from the sale by the Assignee of the Specified Trademarks as referenced in the Certificate), and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively, the "Specified Trademark Collateral").

The Assignor hereby authorizes the Assignee or the Assignee's authorized representative to record this Release with the United States Patent and Trademark Office ("USPTO"), the Canadian Intellectual Property Office ("CIPO") and any other offices as may be necessary to carry out the intention of this Release, and to the extent applicable, the Assignor authorizes and requests that the USPTO and CIPO record this Release.

The Assignor shall execute and deliver any and all documents or other instruments reasonably requested by the Assignee, and at the Assignee's sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

Delivery of an executed signature page to this Release by facsimile or electronic transmission (including .pdf file) shall be effective as delivery of an original signature.

For the avoidance of any doubt, this Release is strictly limited solely and only to the Specified Trademark Collateral and to no other Trademark Collateral. The Assignor continues to maintain, without interruption or impairment, its security interest in all of the Assignee's right, title and interest in, to and under all Trademark Collateral other than the Specified Trademark Collateral. The provisions of the Trademark Security Agreements, and the Pledge and Security Agreement shall, except as modified by this Release, continue in full force and effect.

**THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND
ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK
WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.**

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Assignor has caused this Release to be executed and delivered by its duly authorized officer as of the date first set forth above.

BARCLAYS BANK PLC,
as Collateral Agent

A handwritten signature in black ink, appearing to be 'Ozioma Ejiofor', written over a horizontal line.

By: _____
Name: Ozioma Ejiofor
Title: Assistant Vice President

SCHEDULE I
to
RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS

Specified Trademarks

United States Patent and Trademark Office

Reel/Frame 5439/0392 – 1/9/2015 - Security Interest by Barclays Bank PLC:

Trademark	Serial No.	Filing Date	Reg. #	Reg. Date	Owner
ERTACZO	78125990	05/03/2002	2893833	10/12/2004	VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (now known as Bausch Health Companies Inc.)

Reel/Frame 6280/0114 – 2/13/2018 - Security Interest by Barclays Bank PLC:

Trademark	Serial No.	Filing Date	Reg. #	Reg. Date	Owner
ERTACZO	78125990	05/03/2002	2893833	10/12/2004	VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (now known as Bausch Health Companies Inc.)

Canadian Intellectual Property Office

Trademark	Application No.	Registration No.	Date of Change	Date Recorded	File No.
ERTACZO	1355211	TMA786343	2016-08-22	2016-08-22	254343